The landscape of hematological oncology is facing a potential paradigm shift following the publication of a landmark study by researchers…
Read More
Genprex Secures Canadian Patent for Novel Cancer Therapy Combination
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the…
Read More
UniQure Secures Path to Regulatory Review for Groundbreaking Huntington’s Disease Gene Therapy After FDA Reversal
UniQure has announced a significant turning point in its pursuit of regulatory approval for AMT-130, a pioneering gene therapy aimed…
Read More
Novo Nordisk Transfers Parkinson’s Cell Therapy to Cellular Intelligence, Signaling New Era for AI-Driven Biopharma
In a significant development for the burgeoning field of cell therapy and artificial intelligence in drug discovery, Cellular Intelligence, a…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read More
Ludwig Cancer Research Study Identifies Novel Synergistic Combination Therapy to Overcome Differentiation Block in Acute Myelogenous Leukemia
The landscape of hematological oncology faces a persistent and formidable challenge in the form of acute myelogenous leukemia (AML), a…
Read More
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…
Read More
Cellares, TScan to assess automated manufacturing of TSC-101 therapy
In a significant development poised to accelerate the accessibility of cutting-edge cell therapies, Cellares and TScan Therapeutics have announced a…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read MoreYOU MAY HAVE MISSED
